Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by a mutation in lipoprotein lipase. Credit: Kateryna Kon via Shutterstock.

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder caused by a mutation in lipoprotein lipase. FCS is characterised by the body’s inability to break down fats in the blood, which leads to the accumulation of chylomicrons. This can cause severe health complications, such as pancreatitis and cardiovascular disease.

According to key opinion leaders interviewed by GlobalData, there is an unmet need for drugs that treat severe genetic disorders including FCS and familial hypercholesterolemia (FH). There are currently no FDA-approved therapies to treat FCS.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

One unmet need in the treatment of FCS is the development of new therapies that can more effectively lower triglyceride levels and prevent the complications associated with this disorder. One potential approach is the development of drugs that can specifically target the metabolic pathways involved in the accumulation of chylomicrons in FCS.

Angiopoietin-like protein 3 (ANGPTL3) is a protein that regulates the activity of enzymes involved in the production and clearance of lipoproteins. There are a number of novel small molecule ANGPTL3 inhibitors in development, including Arrowhead Pharmaceuticals’ ARO-ANG3, currently being investigated for the treatment of homozygous FH with plans for Phase III clinical trials.

GlobalData forecasts this drug to launch in the US in 2026 and to reach $442 million in sales by 2028. Arrowhead Pharmaceuticals is also investigating ARO-APOC3, currently in a Phase II clinical study for patients with severe hypertriglyceridemia and mixed dyslipidemia, as well as in a Phase III clinical study for patients with FCS.

See Also:

In March 2023, Arrowhead Pharmaceuticals announced that the FDA has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with FCS. Fast Track designation is a process designed to facilitate the development of drugs to treat serious conditions and fulfil unmet needs, and to allow new drugs to reach patients earlier. GlobalData forecasts that ARO-APOC3 will launch in the US in 2026 and reach $178 million in sales by 2028.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The development of drugs to treat severe genetic disorders has a significant positive impact on individuals, families and society as a whole, leading to better healthcare outcomes, improved quality of life, and advances in medical research.